- The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and various genetic factors, versus rituximab alone
- If approved, the sNDA would expand the FDA's prescribing information for IMBRUVICA in WM as the first chemotherapy-free combination treatment option
- IMBRUVICA is the first and only FDA-approved treatment for patients with WM
PR Newswire
NORTH CHICAGO, Ill., June 25, 2018